Budget & Regulatory Environment in DC Alan Mertz President ACLA

Slides:



Advertisements
Similar presentations
From Cutting Red Tape to Maximizing Net Benefits Alexander T. Hunt U.S. Office of Management and Budget Challenges on Cutting Red Tape Rotterdam, The Netherlands.
Advertisements

CCLA Annual Meeting November 7, 2014 Alan Mertz President, ACLA American Clinical Laboratory Association 1100 New York Avenue, NW Suite 725 West Washington,
Legislative Update 2014 Legislative Session California Clinical Laboratory Association 2014 Annual Conference Arnold and Associates, Inc. Michael J. Arnold.
Legislative Rule-Making Process. Three Different Processes Higher Education 29A-3A-1 et seq State Board of Education 29A-3B-1 et seq All other state agencies.
Budget Politics PS 426 April 7, Budget categories, 2008.
Cap.org v. # CMS Issues Rule on Medicare Payment Cuts in 2014, Other Significant Developments Jonathan Myles, MD, FCAP, Chair, Economic Affairs Committee.
ADMINISTRATIVE LAW P ART 2 Report By: Junen Baja Ruby Concepcion L EGISLATIVE P ROCESS.
Clinical Laboratory Testing: Providing Clinical Evidence for Diagnosis and Treatment Alan Mertz President American Clinical Laboratory Association.
Last Topic - Constitutions of United States and its silent Features Silent Features 1.Preamble 2. Introduction and Evolution 3. Sources 4. Significance.
1 Maryland Health Services Cost Review Commission April 30, 2014 Data and Infrastructure Workgroup Draft Report on Data Requirements for Monitoring.
The Power of the Rare Disease Community… Diane Dorman Vice President, Public Policy National Organization for Rare Disorders (NORD) 1 st International.
Certificate of Public Need Work Group. Certificate of Public Need Work Group. Secretary Bill Hazel, Jr., MD Secretary of Health and Human Resources Initial.
March 2, 2011 Status of the Patent Budget. 2 Steps in the Budget Process Strategic Planning – long term Budget Formulation and Performance Planning -
PPP Legal & Regulatory Framework. PPP Policy In July 2008 GOK approved the PPP policy directive through which: PPPs are identified as a method for investing.
The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress 1 How to Implement a Private Payer Reimbursement Strategy Barbara Grenell.
UPCOMING CHANGES TO IN-VITRO DIAGNOSTICS (IVDs) AND LABORATORY DEVELOPED TESTS (LDTs) REGULATIONS Moj Eram, PhD November 5, 2015.
Fair Go Rates System Dr Ron Ben-David Chairperson MAV Rate Capping Forum 26 November 2015.
Source: National Journal Research, 2015; Jonathan Weisman, “Senate Republicans Rebuff House Colleagues With Their Budget Plan,” New York Times, March 18,
NCHER Legislative Conference Washington, DC Federal Update February 2, 2016 Annmarie Weisman, Office of Postsecondary Education.
The Principles of the United States Constitution.
We The People… Learning about the three branches of our National Government.
Special Meeting on Procedures for Information Exchange November 7, 2007 Geneva Session 1 Anne Meininger United States USA WTO TBT Enquiry Point.
REPUBLIC of the PHILIPPINES. Philippine Legal System Government Structure Three (3) branches of the government: EXECUTIVE LEGISLATIVE JUDICIARY.
House and Senate Energy and Water Appropriation Bills FY 2017 House and Senate Appropriation Bills on Energy and Water Spending Compared to President’s.
1 Regulatory And Cost Containment Issues Affecting Molecular Diagnostics Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology.
August 4, 2016 Brooke Bumpers, Counsel Kathleen A. Peterson, Counsel Christopher H. Schott, Counsel PAMA and the New Medicare Clinical Lab Payment System.
June 6, 2016 | Katharine Conlon, Alexander Perry and Justin Brown Source: National Journal Research, CONGRESSIONAL CALENDAR
Policy & Legislative Update
Legislative Update 2016 Legislative Session
Washington Update PACT Medical Device Group March 7, 2013 Mark Leahey
Proposed Medicaid Hospital Outpatient Prospective Payment System
Fair Go Rates System Dr Ron Ben-David Chairperson
(Model Years ) Jeffrey King Chief, Energy and Climate Programs CEEPC
What is Policy? Julie M. Slavens Indiana School Boards Association
Lab Oversight and Enforcement
Regulatory & Reimbursement Update Kyle Fetter VP & General Manager of Diagnostic Services, XIFIN, Inc.
A Federal Update and Perspective
2012 CCLA Annual Conference
Budget and Appropriations 101
2010 CCLA Annual Conference
American Clinical Laboratory Association
DRAFT FOUO PRE-DECISIONAL
“Health Care Reform Gets Underway – What it Means for the Future of Laboratories… Plus, the Latest on FDA Oversight of LDTs” Alan Mertz, President, American.
California Clinical Laboratory Association 2017 Annual Conference Washington Update Julie Khani, ACLA November 3, 2017.
2012: Future Impact of Health Care Reform on Laboratory Business
The Rulemaking Process
Elaine K Jeter, MD MolDX, Palmetto GBA
R&D Funding in the New Administration and Congress
Washington Update PACT Medical Device Group March 7, 2013 Mark Leahey
George Bearpaw, Director
College of Alameda Integrated Planning and Budgeting Process
Budget & Finance Federal Select Committee March 23, 2017
CCLA 2016 Annual Conference
1115 Demonstration Waiver Extension Summary
Lâle White, CEO, XIFIN, Inc. November 7, 2012
Fair Go Rates System Dr Ron Ben-David Chairperson
Understanding the General State Aid Process: The Players & Phases
Alan Mertz President American Clinical Laboratory Association
Lessons Learned from the 2013 Molecular Diagnostics Gapfill Process
CCLA Legislative Update 2010 Legislative Session
DRG Implementation Overview
Transition Proviso & OSPI Updates:
Congress: The Legislative Branch
OFFICE OF ADVOCACY Created by Congress in 1976.
The Federal Budget Process
S.260/H.R. 873: Transformation to Competitive Employment Act
Maryland Health Services Cost Review Commission April 30, 2014
Rulemaking in iowa.
Charter School Legislation HB 1390 and SB 737.
DMHC Updates ICE Annual Conference November 8, 2005
Presentation transcript:

Budget & Regulatory Environment in DC Alan Mertz President ACLA CCLA November 4, 2016

Summary Budget/Reimbursement Regulatory PAMA Gapfill CLFS 2017 Update Regulatory FDA/LDTs Election & What It Means For Labs Reimbursement Confidential – Do Not Distribute

PAMA In Context CMS Was Proceeding With Repricing Before PAMA Experience with CMS Instructive OPPS 75% Gapfill 60% Congress Was Going to Cut CLFS in Addition to CMS Labs Did Not Have Anything to Negotiate As With Past Threats Statute Provide Some Guardrails Annual Caps on Cuts No Cuts Before 2017, Later 2018 Tech Adjustment Authority Repealed ADLTs Confidential – Do Not Distribute

PAMA Proposed -- Final Rule Applicable Lab Defined by TIN – Defined by NPI Inadequate Time For Implementation – Delay to 2018 Data Collection Period One Year – Reduced to Six Months No Specific Gap Between Data Collect & Report – Six Months Data Reporting Period Three Months Established Data Reporting at CLIA level – Data Reporting at TIN Level Applicable Information Unclear – Patient cost sharing included, bundled payment & zero payment excluded ADLT excluded protein tests – ADLT included protein tests Confidential – Do Not Distribute

Gapfill & 2016 Final Pricing Determinations Process lacks transparency, results in drastic cuts to innovative tests CMS should instruct MACs to provide rationale for rates Without data as basis for rates, can’t evaluate accuracy or fairness Final gapfill rates dramatically lower than private payor rates Final gapfill rates for innovative tests Medicare prices on order of 60% Rates are all over the place, no basis to the criteria for setting rates ACLA filing requests for reconsideration of some codes Confidential – Do Not Distribute

CLFS Update 2017 No Cuts in 2017 from PAMA or Productivity Adjustment Assume 2016 Rates Only Unknown is Whether CPI Will be Applied CMS will Announce Whether CPI (Approx +1%) is When Final CLFS Rule Issued in November 2016 Confidential – Do Not Distribute

The Battle Over Regulation of LDTs Congress Looking At Alternatives to FDA Guidance After Issuing Draft Guidance in October 2014, No Final Guidance as Of November 2016 Law Requires FDA to Notify Congress 60 Days Before Issuing Final Guidance, With Summary of Guidance Two Initiatives in 2016 That Impact Issuance of Final Guidance Both House & Senate Committees Looking at New Pathway for LDTs House Energy & Commerce Committee Senate HELP Committee Important Stakeholder Activity House Appropriations Committee Report Language What Happens in 2016, Next Year? Confidential – Do Not Distribute

Election & What It Means for Labs Control of Congress Watch for Major “Reconcilation Legislation” in 2017 Reimbursement Issues FDA Confidential – Do Not Distribute

Thank You! Alan Mertz amertz@acla.com